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Immunization with heat-inactivated herpes simplex virus type 1 (HSV-1) 2–5 days before ocular infection reduced the
frequency of establishment of latent HSV-1 infection in the trigeminal ganglion (TG); this induction of resistence coincided
with reduced expression of IFN-g mRNA in the TG. Immunization with unrelated antigens was not protective. In part, this
resistance to nervous system invasion correlated with the appearance of serum antibody to HSV-1. Immunization reduced
viral replication in the eye and trigeminal ganglion, and prevented HSV-1 spread to the cerebellum. IFN-g was detected in
immunized mice 4 days postocular infection as determined by plaque reduction using neutralizing Ab to IFN-a/b and IFN-
g. Injection of antibody (Ab) to IFN-a/b and IFN-g administered at the time of immunization did not affect survival. Anti-
IFN-g-treated mice had significantly reduced levels of IFN in their serum. Treatment with anti-IFN-a/b Ab resulted in an
elevation in viral replication as determined by the expression of latency associated transcripts in the TG of mice. Likewise,
there was a significant increase in the CD8, IL-12 (p40), and TNF-a mRNA levels in the TG of the anti-IFN-a/b-treated mice.
TG explant cultures demonstrated that viral load was significantly increased in the TG of anti-IFN-a/b-treated mice relative
to TG of control mice 7 days after infection. The results suggest that exposure to viral antigens 2–5 days before infection
is an important determinant of the extent of HSV-1 spread to the nervous system. Moreover, the data suggest that both an
antibody response and IFN-a/b play a role in limiting the progress of infection from the peripheral tissues to the central
nervous system. q 1997 Academic Press
INTRODUCTION others (Feduchi et al., 1989; Chen et al., 1993) and by
facilitating the development of humoral immunity to HSV-
Herpes simplex virus type-1 (HSV-1) is a highly virulent 1 (Stevens and Cook, 1974).
pathogen in mice frequently spreading to the central ner- The success of HSV-1 in evading the immune re-
vous system (CNS) and causing fatal encephalitis or, sponse includes a reduction in MHC class II antigen
alternatively, residing in the sensory ganglia (dorsal root expression during the acute infection (Lewandowski et
or trigeminal ganglia) in a latent state. The immune re- al., 1993, 1994) and interference with MHC class I gene
sponse to HSV-1 is rapid and vigorous encompassing expression during latency (Pereira et al., 1994). Viral DNA
innate and acquired immune responses. The innate im- synthesis within the infected cell continues resulting in
mune response to HSV-1 involves both NK cells (Engler a lytic infection or, alternatively, declines resulting in a
et al., 1981; Tamesis et al., 1994) and IFN-a (Linnavuori state of latency (Kosz-Vnenchak et al., 1993; Nichol et
and Hovi, 1993). The presence of IFN-a affords immedi- al., 1996). However, the ‘‘latent’’ state might be defined
ate antiviral action as demonstrated in mouse splenic
as low level persistence as evidenced by the detection
macrophages where IFN-a inhibition of HSV-1 replication
of viral transcripts (Kramer and Coen, 1995; Hay et al.,
is reported to be due to a block in immediate early (a) and
1995) and protein (Green et al., 1981). Consistent with
delayed early (b) viral gene transcription rates (Straub et
this interpretation is the expression of cytokine and
al., 1986; Mittnacht et al., 1988) or as revealed in HeLa
chemokine transcripts and proteins long after the estab-
cells where IFN-a treatment results in the production of
lishment of latency (Shimeld et al., 1995; Cantin et al.,
defective virions (Munoz and Carrasco, 1984). Similar to
1995; Liu et al., 1996; Halford et al., 1996), suggesting
NK cells, neutrophils (Tumpey et al., 1996), CD4/ lympho-
the continued stimulation of effector cells by viral antigen.cytes (Nash et al., 1987; Manickan and Rouse, 1995),
Evidence indicating that expression of viral proteins orand CD8/ lymphocytes (Rouse et al., 1983; Bonneau and
spontaneous reactivation of virus occurs during latencyJennings, 1989; Simmons and Tscharke, 1992) antago-
has recently been obtained. Treatment of latent mice withnize viral replication either directly or indirectly through
acyclovir significantly reduces IFN-g gene expressionthe secretion of cytokines including TNF-a, IFN-g and
as well, and, antibody production against selected viral
proteins including glycoprotein D and glycoprotein B
compared to vehicle-treated latent mice (W. P. Halford1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (504) 568-2918. E-mail: dcarr@Lsumc.edu. et al., in press).
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There are differences in viral strain pathogenicity and, 1 indicator cells was performed as previously described
(Stevens and Cook, 1971).as well, mouse strains differ in their susceptibility to HSV-
1 infection. Evidence indicates that the survival of HSV-
Infection of mice1-infected mice is the result of whether an immune re-
sponse develops before HSV-1 reaches the CNS. In sus-
Mice were infected with HSV-1 (McKrae strain) grown
ceptible mice the probability of significant morbidity or
in Vero cells, as previously described (Halford et al., 1996).
death increases with the size of the HSV-1 inoculum and
Female ICR mice (25–34 grams, Harlan–Sprague–Daw-
is magnified by immunosuppressive treatment (Oakes et
ley, Indianapolis, IN) were anesthetized by IP administra-
al., 1980; Kintner and Brandt, 1995). Conversely, survival
tion of 0.1 ml PBS containing xylazine (2 mg/ml; 6.6 mg/kg)
of HSV-1-infected mice is favored by a smaller HSV-1
and ketamine (30 mg/ml; 100 mg/kg). Following corneal
inoculum and treatments which favor early immune rec-
scarification with a 25-guage needle, tear film was blotted
ognition of viral infection (McKendall et al., 1979; Oakes
from the eyes, and mice were inoculated with 300 plaque
and Lausch, 1984). For example, passive immunization
forming units (PFU) or as indicated of HSV-1 in each eye.
has been used to decrease the mortality and morbidity
At the time of infection, designated groups were passively
associated with primary infection and thus increase the
immunized ip with 0.1 ml of rabbit antiserum to HSV-1
fraction of infected mice available for use in studying
(complement-dependent neutralization titer of 2500). Infec-
HSV-1 latency (Shimeld et al., 1989).
tion was verified by swabbing mouse eyes 2 days postin-
The impetus for this study came from a need to protect
fection (p.i.), placing the swabs in CV-1 monolayer cul-
mice during acute HSV-1 infection, since mortality of pas-
tures, and observing CV-1 cells for cytopathic effect (CPE).
sively immunized mice is often 30%, and thus improved
Animals were handled and maintained in accordance with
yields of HSV-1 latently infected mice is desired. We also
the National Institutes of Health guidelines on the Care
were motivated to better understand the nature of the
and Use of Laboratory Animals, publication No. 85-23,
earliest host defense responses to HSV-1 which protect
revised 1996.
mice from developing encephalitis. When HSV antigen
(Ag) is administered to mice 2–4 weeks prior to infection, Active immunization of mice
HSV-1 spread from the inoculation site is limited and
Mice were given 0.1 ml of heat inactivated HSV-1 ip.mortality is altogether prevented (Erturk et al., 1992; Mor-
One-half-milliliter aliquots of HSV-1 (107 PFU/ml) were heat-rison et al., 1994). We reasoned that active immunization
inactivated at 657 water bath for 20 min, tested on CV-10–5 days prior to infection should initiate HSV-specific
cells to confirm inactivation, and stored frozen until used.immunity before virus reached the CNS, but this would
be too brief to prevent HSV-1 spread from the eye into
Reverse transcription-polymerase chain reactionthe trigeminal ganglion (TG). The first of these points
proved to be true. Intraperitoneal (ip) administration of
Reverse transcription-polymerase chain reaction (RT-
HSV-1 Ag 2–5 days prior to ocular infection protected
PCR) of TG mRNA was performed as described (Halford
mice from developing HSV-1 encephalitis. However,
et al., 1996). Briefly, TG RNA was extracted in Ultraspec
HSV-1 Ag injection also significantly interfered with the
RNA isolation reagent (Biotecx Inc., Houston, TX). First
capacity of HSV-1 to latently infect the TG. The results
strand cDNA was synthesized using AMV reverse tran-
demonstrate that (1) protection from HSV-1 encephalitis
scriptase (Promega Corp., Madison, WI). PCR was per-
is induced rapidly after exposure of mice to viral Ag and
formed in a thermal cycler (MJ Research, Watertown, MA)
that (2) immune status in the form of innate and acquired
with 35 cycles of 947 (1*159) r 57–607 (1*159) r 727 (309).
immunity at the time of infection plays a major role in
PCR primers (LSU Medical Center Core Laboratories,
the spread of HSV-1 to the TG, the establishment of la-
New Orleans, LA) are listed in Table 1. IFN-a (consensus
tency, and infection of the central nervous system.
sequence for IFN-a1, 2, and 7), CD4, and CD8 primer
sequences were obtained from Clontech Laboratories,
Inc. (Palo Alto, CA), and IL-12 primer sequences wereMATERIALS AND METHODS
from Kanangat et al. (1996). Following electrophoresis,
Virus and cells ethidium bromide-stained PCR products were visualized
with an EagleEye II still video capture system (Stra-
The Vero and CV-1 African green monkey kidney cell
tagene, La Jolla, CA). Densitometric analysis of gel im-
lines were obtained from the American Type Culture Col-
ages was performed using Imagequant 3.3 software (Mo-
lection (Rockville, MD). Cells were cultured in RPMI-1640
lecular Dynamics, Sunnyvale, CA).
(Irvine Scientific, Santa Ana, CA) supplemented with 5%
FBS (Life Technologies, Gaithersburg, MD) and an antibi- Serum IFN levels
otic/antimycotic solution (Atlantic Biologicals, Atlanta,
GA). Cells were incubated at 377 in an atmosphere of 5% Blood was collected from mice 4 days following ocular
infection with HSV-1. Serum obtained from the blood wasCO2 and 95% humidity. Coculture of TG explants with CV-
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TABLE 1
Oligonucleotide Primer Pairs
Product size
Primer (bp) Sequence
GAPDH-a 239 5*-GAATCTACTGGCGTCTTCACC
GAPDH-b 5*-GTCATGAGCCCTTCCACGATGC
ICPO-3* — 5*-TTCGACCAGGGCACCCTAGT
LAT-a 195 5*-GACAGCAAAAATCCCCTGAG
LAT-b 5*-ACGAGGGAAAACAATAAGGG
IL-10-a 256 5*-GGACAACATACTGCTAACCGACTG
IL-10-b 5*-AAAATCACTCTTCACCTGCTCCACTT
IL-12/p40-a 336 5*-CAGTTCAATGGGCAGGGTCTCCTC
IL-12/p40-b 5*-CCACTCACATCTGCTGCTCCACAA
IFN-a-a 294 5*-GACTCATCTGCTGCTTGGAATGCAACCCTCC
IFN-a-b 5*-GACTCACTCCTTCTCCTCACTCAGTCTTGCC
IFN-g-a 237 5*-AACGCTACACACTGCATCTTGG
IFN-g-b 5*-GACTTCAAAGAGTCTGAGG
TNF-a-a 384 5*-GCCTGTAGCCCACGTCGTAG
TNF-a-b 5*-TTGGGCAGATTGACCTCAGC
CD4-a 615 5*-TGTGCCGAGCCATCTCTCTTAGG
CD4-b 5*-GCACTGAGAGTGTCATGCCGAAC
CD8-a 513 5*-ATGCAGCCATGGCTCTGGCTGG
CD8-b 5*-GCATGTCAGGCCCTTCTGGGTC
RANTES-a 271 5*-GAAGATCTCTGCAGCTGCCCT
RANTES-b 5*-GCTCATCTCCAAATATGTTGA
IFN-g-a 237 5*-AACGCTACACACTGCATCTTGG
IFN-g-b 5*-GACTTCAAAGAGTCTGAGG
Note. a, sense; b, antisense.
assayed for IFN bioactivity according to the method of gland), or anti-IFN-g Ab (Lee Biomolecular Research Lab.
Inc.) (neutralizing capacity of 370 U/administration), con-Johnson (1981) and using neutralizing Ab to IFN-a/b and
IFN-g. In the neutralization experiment, Ab (neutralizing trol rabbit serum, or vehicle (PBS) IP at the time of immu-
nization (0.1 ml of heat-inactivated HSV-1 equivalent tocapacity  128 units) to IFN-a/b (Lee Biomolecular Re-
search Lab. Inc., San Diego, CA) and IFN-g (Lee Biomo- 107 PFU/ml) and again 72 hr after immunization. Five
days later, the mice were infected with 450 PFU/eye oflecular Research Lab. Inc.) or normal rabbit serum was
incubated with supernatants for 60 min at room tempera- HSV-1. The percentage survival of all treatment groups
was recorded. Serum was obtained by retro-orbitalture prior to addition to CV-1 monolayers along with 2 1
106 PFUs of virus. bleeding at designated times. Mice that survived the in-
fection were sacrificed following the establishment of
HSV-1 antibody ELISA latency (i.e., 30 days postinfection (p.i.), the TG were col-
lected, and RNA was extracted for the determination ofSucrose-purified lysates of HSV-1 and uninfected CV-
cytokine mRNA by RT-PCR.1 cells were used as coating Ag for 96-well microtiter
plates and were prepared as previously described (Half-
Measurement of HSV-1 titers in the tissuesord et al., 1996). Dilutions of mouse serum (uninfected,
immunized, immunized and infected samples) were incu-
TG, eyes, and cerebella were weighed following re-
bated in quadruplicate wells, washed, incubated with
moval and homogenized in 0.5 ml RPMI-1640 containing
alkaline phosphatase-conjugated anti-mouse IgG (heavy
5% FBS in a 2.0-ml microfuge tube. Homogenates were
and light chain specific; TAGO, Burlingame, CA), washed,
clarified by centrifugation for 1 min at 13,000 g. HSV-1
and incubated with para-nitrophenyl phosphate sub-
titer in clarified supernatants was determined by plaque
strate. Optical density at 405 nm was determined after 1
assay. Virus load was calculated as [plaque forming units
hr incubation at 377. Serum anti-HSV-1 Ab was measured
per ml 1 sample volume/tissue weight] and expressed
as previously described (Halford et al., 1996).
in PFU/ml.
Treatment of actively immunized mice with anti-IFN
StatisticsAbs
ICR mice were given anti-IFN-a/b (Lee Biomolecular Analysis of normally distributed data was done by one-
way ANOVA and a post hoc multiple comparison testResearch Lab. Inc.), anti-IFN-a (Serotec, Oxford, En-
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TABLE 2
Survival Following Active Immunization Is Antigen-Specific a
HSV-1 inoculum
Treatment 450 4500 45000 S survival
Diluent b 0/5 ND c ND 0/5
Rabbit serum d 0/6 ND ND 0/6
VSV e 0/7 ND ND 0/7
CV-1 lysate f 3/6 0/3 0/3 3/12
HSV-1 g 5/6 2/3 2/3 9/12*
a Reported as fraction of mice surviving 14 days pi. The inoculum is
reported as PFU HSV-1/eye. This table is a representative experiment
which has been repeated 4 times (n  12–15 mice) in which mortality
FIG. 1. Protective effect of active immunization is dependent on tim- associated with ocular HSV-1 infection did not exceed 33% in HSV
ing of HSV antigen injection. A representative experiment showing (-d5)-treated mice when challenged with 450–45,000 PFU HSV-1 per
percentage of survival of HSV-1-infected mice (n  7 per treatment eye.
group) as a function of time (days postinfection). Mice were infected b RPMI-1640/5% FBS given 5 days before infection.
with 450 PFU HSV-1 per eye. Vehicle-treated mice were given RPMI- c Not determined.
1640 with 5% FBS 2 days before infection. Passively immunized mice d Normal rabbit serum given 5 days before infection.
were given rabbit antiserum to HSV-1 at the time of infection. HSV-1 e Heat-inactivated, sucrose-purified vesicular stomatitis virus given
antigen was given to mice at the time of (0d0), 2 days before (0d2), 5 days before infection.
or 5 days before (0d5) HSV-1 infection. f Heat-treated CV-1 Ag given 5 days before infection.
g Heat-inactivated HSV-1 Ag given 5 days before infection.
* P  0.05 by Fisher’s exact test when survival in HSV-1 Ag-treated
(Scheffe) or t test (Tukey). Differences in survival after mice was compared to either CV-1 Ag, VSV, serum, or diluent-treated
HSV-1 infection and the kinetics of HSV-1 reactivation mice.
from TG explants were evaluated by the Cox–Mantel test
(Cox, 1972).
vation was significantly delayed in the TGs of HSV (0d5)-
treated mice (Fig. 2; P  0.05, Cox–Mantel test).RESULTS
RT-PCR was used to compare the abundance of LAT
Protection is rapidly induced following exposure to and interferon (IFN)-g mRNA in TG of passively and ac-
viral antigen tively immunized mice. By this technique, we routinely
Survival was compared in mice given HSV-1 Ag at
different times before infection. HSV-1 Ag given 5 days
before infection (HSV 0d5) prevented encephalitis and
death in 85% of mice (Fig. 1). HSV-1 Ag given at the time
of infection (i.e., HSV 0d0) did not prevent encephalitis.
An equal percentage (57%) of mice given HSV-1 Ag 2
days prior to infection (HSV 0d2) or rabbit anti-HSV-1
antibody (passive) survived (Fig. 1). To determine if the
protection conferred by active immunization was viral Ag-
specific, mice were given non-cross-reacting Ags 5 days
prior to ocular HSV-1 infection. None of the mice given
the diluent (RPMI-1640 containing 5% FBS), normal rabbit
serum, heat-killed vesicular stomatitis virus, or CV-1 Ag
survived a challenge of 450 PFU HSV-1/eye (Table 2).
However, the majority of HSV-1 Ag-treated mice were
FIG. 2. Reactivation kinetics of HSV-1 from trigeminal ganglion ex-protected from encephalitis at all doses (Table 2).
plants. Mice were intraperitoneally given either rabbit anti-HSV-1 anti-
serum at the time of infection (passive immunization) or HSV-1 antigenEstablishment of latency in actively immunized mice
(active immunization) 5 days prior to infection (0d5). Trigeminal ganglia
were obtained from mice 30 days postinfection (n  7/group), andTo determine if viral latency was established in actively
cocultured with CV-1 indicator cells. Cultures were observed daily forimmunized mice, TGs from infected mice 30 days PI were
the appearance of CPE. Results are reported as percentage of culturescocultured with CV-1 cells and observed for HSV-1 reacti-
showing CPE (% reactivation) at times after culture establishment
vation. Reactivation occurred 7/7 TG from passively immu- (days). To confirm that CPE was virus induced, 0.1 ml of culture super-
nized mice, but was detected in 4/7 TG from HSV (0d5)- natant was transferred to a secondary CV-1 cell culture which was
then observed for the development of CPE.immunized mice (Fig. 2). Also, the kinetics of HSV-1 reacti-
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FIG. 3. Interferon-g mRNA is detected less often in trigeminal ganglia of actively immunized mice. RT-PCR analysis was used to compare
expression of HSV-1 latency-associated transcripts (LAT) and interferon-g mRNA in trigeminal ganglia from two uninfected mice (UI), and six HSV-
1 latently infected mice (i.e., 67 days postinfection) that were either given rabbit antiserum to HSV-1 at the time of infection (passive) or HSV-1
antigen 5 days prior to infection (0d5). Glyceraldehyde-3-phosphodehydrogenase (G3PDH) served as a positive control of RT-PCR.
observe persistent cytokine gene expression in 80–90% serum of HSV-1 Ag-immunized mice. Serum concentra-
tions of anti-HSV-1 Ab were higher in HSV (0d5)-treatedof HSV-1 latently infected TG (Halford et al., 1996). While
RT-PCR revealed no significant differences in LAT levels, mice compared to diluent-treated controls at 4 days p.i.
(Fig. 4). Serum titers of anti-HSV-1 Ab in passively immu-IFN-g mRNA was detected less frequently in TG from
HSV (0d5)-treated mice than passively immunized con- nized and CV-1 Ag (0d5)-treated mice were identical to
the titers in diluent-treated controls at all the time pointstrols (Fig. 3). In the summed results of three experiments,
while IFN-g mRNA was detected in 11/13 TG from pas- (data not shown). Consistent with the lower survival rates
seen in HSV (0d2)-treated mice, serum anti-HSV-1 Absively immunized mice, IFN-g mRNA was only detected
in 4/13 TG from actively immunized mice (P  0.015,
as determined by Fisher’s exact test). Together with the
TABLE 3delayed kinetics of HSV-1 reactivation from TG explants
and the reduced levels of IFN-g mRNA suggest that un- Active Immunization Inhibits Viral Spread from the Eye
like passive immunization, active immunization interferes to the Peripheral and Central Nervous Systems a
with the establishment of latent HSV-1 infection in the
Days PITG.
2 4 6 8Active immunization reduces HSV-1 spread during
primary infection
Eyes
The spread of HSV-1 from the eyes to the peripheral Diluent b 5.0 { 0.3 f 5.0 { 0.4 5.4 { 0.6 4.8 { 1.4
Passive c 5.6 { 0.1 4.4 { 0.1 4.6 { 0.5 1.4 { 1.1(TG) and central nervous systems (cerebellum) was com-
HSV (-d2) d 5.0 { 0.4 4.8 { 0.2 3.7 { 0.8* 2.3 { 1.1pared in diluent-treated, passively immunized, and ac-
HSV (-d5) e 3.0 { 1.5 2.2 { 1.1 1.6 { 0.8* ND gtively immunized mice. The PFU titer in the eyes and TG
TG
of HSV (0d2)-treated mice was comparable to that of Diluent 2.1 { 1.1 5.4 { 0.4 6.0 { 0.4 5.1 { 0.8
passively immunized mice (Table 3). At 2, 4, 6, and 8 Passive 2.2 { 1.1 1.5 { 1.5 3.0 { 1.7 ND
HSV (-d2) 0.9 { 0.9 2.4 { 1.2 2.4 { 1.2* 0.9 { 0.9*days PI, HSV-1 titers in the eyes and TG of HSV (0d5)-
HSV (-d5) ND* ND* 2.4 { 1.2* 1.0 { 1.0*treated mice were 100 to 10,000-fold lower than in dilu-
Cerebellument-treated controls (Table 3). Likewise, HSV-1 titers in
Diluent ND ND 2.9 { 0.7 3.0 { 0.8
the eyes of HSV (0d5)-treated mice were 30 to 1000-fold Passive ND ND 1.6 { 0.8 ND*
lower than passively immunized mice, and the spread of HSV (-d2) ND ND ND* ND*
HSV (-d5) ND ND ND* ND*HSV-1 to the TG was delayed compared to passively
immunized mice. Virus was found in the TG 2 days after
a Mice were inoculated with 450 PFU/eye. Data is reported in loginfection in all groups except the HSV (0d5) mice in
[PFU/g tissue]. To allow log transformation of all data, samples in which
which virus was not found until day 6 (Table 3). Presum- HSV-1 was not detected were assigned a value of 1.
ably, the reduced spread of HSV-1 from the eyes to the b RPMI-1640 with 5% FBS given 5 days before infection.
c Rabbit antiserum to HSV-1 given at the time of infection.TG of HSV (0d5)-treated mice is in part responsible for
d Heat-inactivated HSV-1 given 2 days prior to infection.the reduced establishment of HSV-1 latency.
e Heat-inactivated HSV-1 given 5 days prior to infection.
f Virus titers reported as mean { SEM log [PFU/g tissue] (n  3Anti-HSV-1 antibody response in actively immunized
mice/group).mice
g Not detected.
Serum antibody responses to HSV-1 were measured * P  0.05, as determined by ANOVA and Tukey’s post hoc t test
comparing each treatment group to diluent-treated controls.to determine the time of appearance of antibody in the
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and more viral Ag was present in anti-IFN a/b-treated
mice.
Anti-IFN-a/b increases viral load and cytokine
expression in the TG of immunized mice
The difference in viral titer between the control- and
anti-IFN-a/b-treated mice suggests that there may be an
increase in viral Ag expressed in the anti-IFN-a/b-treated
group. To examine this possibility, HSVd-5-immunized
mice were treated with anti-IFN-a/b, anti-IFN-g, or con-
trol Ab and cytokine and T cell-associated marker CD4
and CD8 mRNA levels in the TG were determined follow-
ing the establishment of latency (i.e., 30 days p.i.). CD4
mRNA was not detectable in any of the samples surveyed
by RT-PCR. The results show that TG CD8 mRNA levels
FIG. 4. Early induction of anti-HSV-1 antibody following active immu- are significantly elevated in the immunized HSVd-5 mice
nization. Serum titers of anti-HSV-1 antibody are reported as mean { treated with anti-IFN-a/b Ab compared to all other
SEM OD405 nm, as determined by ELISA performed on mouse serum groups (Fig. 5, Table 6). Treatment of immunized mice
collected at 2, 4, 6, and 8 days postinfection (n  3 mice per treatment
with anti-IFN-a/b but not anti-IFN-g Ab also resulted ingroup per time point). Vehicle-treated mice were given RPMI-1640 with
a significant increase in the mRNA for TNF-a and IL-125% FBS 5 days before infection. HSV-1 antigen was given to mice either
2 days (0d2) or 5 (0d5) days before infection. Uninfected (UI)/HSV p40 in the TG of latent mice compared to the immunized
(0d5)-treated mice were given HSV-1 antigen at the same time as HSV HSVd-5 mice treated with control Ab (Fig. 5, Table 6).
(0d5)-treated mice, but were not subsequently infected with HSV-1. Although not statistically significant, all other cytokine
Passively immunized mice and mice given CV-1 antigen 5 days before
transcripts measured were elevated in the anti-IFN-a/b-infection had low to undetectable levels of anti-HSV-1 immunoglobulin
treated mice compared to the control Ab-treated group,in their serum 2–8 days postinfection (data not shown). *P  0.05, as
determined by ANOVA and Tukey’s post hoc t test comparing each suggesting that these animals are not able to control
group to vehicle-treated controls. viral replication to the same extent as the other groups
of mice. For example, RT-PCR for the detection of IFN-g
mRNA showed that whereas only 3/8 HSV (0d5) micetiter was low at days 4 and 6 and was elevated by day
treated with control rabbit serum or 4/8 HSV (0d5) mice8 (Fig. 4). Uninfected, HSV (0d5)-treated mice were sam-
treated with anti-IFN-g antiserum had detectable IFN-gpled on the same days as the Ag-treated, infected mice.
transcripts, 6/8 HSV (0d5) mice treated with anti-IFN-a/The infected, HSV (0d5)-treated mice did not have signifi-
b antiserum were positive. In addition, the latency asso-cantly higher levels of serum anti-HSV-1 Ab than the
ciated transcript (LAT) was also elevated in the immu-uninfected, HSV (0d5)-inoculated mice at any of the time
nized HSVd-5-anti-IFN-a/b-treated mice compared to thepoints, suggesting that the anti-HSV-1 Ab response was
other groups. If the number of HSV-1 latently infectedthe result of active immunization and occurred indepen-
neurons is increased in immunized, HSVd-5 anti-IFN-a/b-dently of the ocular infection (Fig. 4). However, whether
treated mice compared to the other groups, there shouldthe antibody in the noninfected versus the actively immu-
be an increase in infectious virus in acutely infected micenized mice is predominantly IgM or IgG and thus, sug-
or an increase in the number of TG that harbor infectiousgesting a primary or secondary response to antigen ex-
virus. To address this question, HSVd-5-immunized miceposure, has not been determined.
that were treated with control or anti-IFN Abs and subse-
quently infected with HSV-1 were sacrificed 7 days p.i.In vivo neutralization of interferon does not affect
and the TG harvested and assayed for the quantity ofsurvival of immunized mice
infectious virus. The results show that anti-IFN-a/b-
An interferon (IFN) neutralization experiment was per- treated, HSVd-5-immunized mice had an increase in the
formed to determine if IFN was an essential component occurrence and quantity of virus isolated from TG homog-
of protection elicited by heat-inactivated HSV-1. Neither enates compared to control-treated or anti-IFN-a-treated
anti-IFN-a/b nor anti-IFN-g Ab treatment reduced the HSVd-5-immunized mice (Table 7).
survival of HSV (0d5)-treated mice even though the anti-
IFN-g treatment significantly reduced serum IFN-g levels DISCUSSION
(Table 4). However, at 30 days p.i., there was a significant
increase in the Ab titer in HSV-1 (0d5)-immunized mice It was found that 20% of actively immunized mice de-
veloped herpetic encephalitis while 50% of passively im-treated with anti-IFN-a/b Ab compared to the group of
immunized (HSV 0d5) mice treated with normal rabbit munized mice and 100% of the control mice developed
the disease. Both active and passive immunization en-serum (Table 5), suggesting that more HSV-1 replication
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TABLE 4
Survival of Immunized Mice Treated with Anti-IFN-a/b or Anti-IFN-g Ab a
Immunization Treatment Survival b [IFN] c Anti-HSV-1 Abd
None Diluent e 0/10 42 { 14 0.138 { 0.028
None Anti-HSV-1 Ab f 5/10 39 { 10 0.135 { 0.050
HSVd-5 Normal rabbit serum g 8/10 24 { 5 1.110 { 0.163
HSVd-5 Anti-IFN-a/b Ab h 7/10 26 { 5 1.239 { 0.147
HSVd-5 Anti-IFN-g Ab i 8/10 9 { 2* 1.255 { 0.157
a Mice (n  10/group) were infected with 450 PFU of HSV-1 per eye.
b Reported as the fraction of mice surviving 14 days pi.
c Serum concentrations (units/ml) sampled 4 days following ocular infection with HSV-1. One unit is defined as the reciprocal of the highest
serum dilution which decreases vesicular stomatitis virus-induced CPE on LGAL cells by 50%.
d Serum concentrations of anti-HSV Ab obtained 4 days pi, as determined by ELISA, and reported as mean { SEM OD405 nm (n  5 mice/group).
e Mice were given RPMI-1640 supplemented with 5% FBS i.p. 5 days prior to infection.
f Mice were given anti-HSV-1 rabbit serum at the time of infection.
g Heat-inactivated HSV-1 was given i.p. 5 days prior to infection. Normal rabbit serum was given 5 and 2 days prior to infection.
h Heat-inactivated HSV-1 was given i.p. 5 days prior to infection. Rabbit anti-IFN-a/b Ab (neutralization capacity  370 units/injection) was
administered i.p. 5 and 2 days prior to infection.
i Heat-inactivated HSV-1 was given i.p. 5 days prior to infection. Rabbit anti-IFN-g Ab (neutralization capacity  370 units/injection) was given
i.p. 5 and 2 days prior to infection.
* P  0.05 comparing the anti-IFN-g treated mice to the control (normal rabbit serum)-treated mice as determined by ANOVA and Tukey’s t test.
hanced survival, but the outcome of HSV-1 infection in nervous systems. In support of these results, a recent
study found that the number of LAT/ neurons in TG ofactively immunized mice differed substantially from that
of mice receiving anti-HSV-1 antiserum. Specifically, im- immunized mice was less than 1% of that observed in
naive controls (Morrison and Knipe, 1994). However, themunization with heat-killed HSV-1 results in: (1) an early
serum Ab response, (2) protection that is relatively insen- mechanism(s) of protection against neuron infection was
not investigated in this study (Morrison and Knipe, 1994).sitive to increasing challenge doses of HSV-1, (3) a
change in the kinetics of viral spread from the eye to the Because HSV-1 reactivation frequency correlates with
the number of latently infected neurons in TG (Perng etTG, and (4) reduced frequency of establishment of la-
tency in the TG. Collectively, the results suggest that the al., 1996), immune status at the time of primary HSV-1
infection may be an important determinant in the proba-immune status at the time of infection significantly affects
the degree of HSV-1 spread to the peripheral and central bility of future herpetic recurrences.
TABLE 5
Serum Titers of Immunized Mice Treated with and without Anti-IFN Abs a
Treatment 1:5 b 1:25 1:125 1:625 1:3125 1:15625 1:78125
Anti-HSV-1 Abc 0.428 { 0.054 d 0.475 { 0.045 0.378 { 0.031 0.237 { 0.014 0.091 { 0.015 ND e ND
Control Ab / HSVd-5f 0.328 { 0.062 0.357 { 0.081 0.387 { 0.053 0.371 { 0.031* 0.238 { 0.026** 0.087 { 0.018 ND
Anti-IFN-g Ab / HSVd-5g 0.287 { 0.64 0.378 { 0.077 0.413 { 0.033 0.374 { 0.018* 0.273 { 0.019** 0.121 { 0.017** 0.017 { 0.005
Anti-IFN-a/b Ab / HSVd-5h 0.477 { 0.078 0.517 { 0.046 0.481 { 0.051 0.408 { 0.040** 0.308 { 0.029**,Ç 0.127 { 0.011**,Ç 0.029 { 0.007**,Ç
a Mice (n  5–8/group) ocularly infected with HSV-1 were sacrificed on day 30 p.i. and serum collected was assayed for anti-HSV-1 reactivity
by ELISA.
b Dilution of mouse serum.
c Rabbit anti-HSV-1 serum given i.p. at the time of infection.
d Serum concentration reported as mean { SEM OD405 nm .
e Not detected.
f Heat-inactivated HSV-1 given 5 days prior to infection. Normal rabbit serum administered 5 and 2 days prior to infection.
g Heat-inactivated HSV-1 given 5 days prior to infection. Anti-IFN-g Ab (neutralization capacity  370 units/injection) given 5 and 2 days prior to
infection.
h Heat-inactivated HSV-1 given 5 days prior to infection. Anti-IFN-a/b Ab (neutralization capacity  370 units/injection) given 5 and 2 days prior
to infection.
* P  0.05, **P  0.01, comparing treated group to anti-HSV-1-treated mouse group as determined by ANOVA and Scheffe multiple comparison
test.
Ç P  0.05, comparing the anti-IFN-a/b-treated HSVd-5 group to the normal rabbit serum HSVd-5-treated group as determined by ANOVA and
Scheffe multiple comparison test.
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FIG. 5. Effects of anti-IFN Ab treatment on cytokine transcription in the TG of immunized mice latently infected with HSV-1. A representative figure
showing RT-PCR analysis of trigeminal ganglion samples from mice that were immunized with HSV-1 antigen 5 days (D5) prior to ocular infection
with HSV-1. Mice receiving normal rabbit serum (Control Ig), anti-IFN-a/b Ab, or anti-IFN-g Ab were administered Ab i.p. at the time of and 72 hr
after immunization with heat-inactivated HSV-1. Anti-HSV-1 Ab (passive) was given at the time of ocular infection. See Table 6 for a summary of
the results.
Evidence for a similar rapid protective phenomenon has induction of IFN-a (Hendricks et al., 1991). These investi-
gators found that intravenous administration of inactivatedbeen reported. One group found that mice were protected
from HSV-1 strain WAL when coinfected i.p. with a nonen- HSV-1 concurrent with ocular HSV-1 infection resulted in
elevated serum IFN-a levels, restricted HSV-1 spread incephalitogenic HSV-1 strain ANG (Schroder et al., 1983).
These investigators also reported that inactive viral Ag the eye, and a reduced CTL response to HSV-1. While anti-
IFN-a/b treatment reversed the effect of reduced HSV-1was protective when administered 24 hr before IP infec-
tion with HSV-1 WAL. Another group suggested that the replication in the eye, it had no effect on the reduced CTL
response to HSV Ag-treated mice (Hendricks et al., 1991).rapid protection against HSV-1 observed following intrave-
nous administration of inactivated HSV-1 is due to the Because the immune response increases in proportion to
TABLE 6
Anti-IFN-a/b Treatment Increases Cytokine mRNA Levels in the TG of Latent HSV-1 Infected Mice a
Anti-HSV-1 HSVd-5 / HSVd-5 / HSVd-5 /
Transcript Ab b control Ab c anti-IFN-a/b Ab d anti-IFN-g Ab e Uninfected f
LAT 0.42 { 0.12 0.39 { 0.17 0.75 { 0.24 0.46 { 0.15 ND g
CD8 2.7 { 0.25 3.1 { 0.23 4.2 { 0.5* 2.8 { 0.45 0.58 { 0.29
IFN-g 0.12 { 0.09 0.02 { 0.01 0.16 { 0.07 0.06 { 0.03 ND
TNF-a 0.09 { 0.05 0.07 { 0.02 0.19 { 0.04* 0.11 { 0.03 0.02 { 0.01
IL-12/p40 0.46 { 0.08 0.61 { 0.24 1.5 { 0.37* 0.59 { 0.19 0.08 { 0.07
RANTES 0.6 { 0.16 0.49 { 0.23 0.47 { 0.11 0.41 { 0.18 0.02 { 0.01
IL-10 h 0.25 { 0.06 0.19 { 0.05 0.39 { 0.14 0.18 { 0.01 ND
IFN-a 2.0 { 0.2 1.3 { 0.5 2.5 { 0.9 1.6 { 0.2 0.9 { 0.8
a Mice (n  8/group) ocularly infected with HSV-1 were sacrificed on day 30 p.i. and TG were collected, RNA extracted and assayed for cytokine
mRNA by RT-PCR. The numbers are reported as a ratio with the housekeeping gene, GAPDH, as determined by densitometry of ethidium bromide-
stained RT-PCR products. This table represents a summary of two independent experiments. A representative experiment is shown in Fig. 5.
b Rabbit anti-HSV-1 serum given at the time of infection.
c Heat-inactivated HSV-1 given 5 days prior to infection. Normal rabbit serum given 5 and 2 days prior to infection.
d Heat-inactivated HSV-1 given 5 days prior to infection. Anti-IFN-a/b Ab (neutralization capacity  370 units/injection) given 5 and 2 days prior
to infection.
e Heat-inactivated HSV-1 given 5 days prior to infection. Anti-IFN-g Ab (neutralization capacity  370 units/injection) given 5 and 2 days prior to
infection.
f Uninfected mice (n  2) values are shown as basal measurements.
g Not detected.
h IL-10 values were only measured using an n  3/group.
* P  0.05 comparing the HSVd-5 immunized mice treated with anti-IFN-a/b Ab to all other groups of mice as determined by ANOVA and Tukey’s
post hoc t test.
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TABLE 7 Although early Ab production provides an index of B
lymphocyte sensitization, inactivated HSV-1 probably alsoAnti-IFN-a/b Increases HSV-1 Yield in the TG
stimulated HSV-specific T effector cells which secreteduring Acute Infection a
cytokines that mediate antiviral effector mechanisms.
Treatment Detectable HSV-1 b [HSV-1] c While there was detectable serum IFN-g in the ocularly
HSV-1-infected mice, IFN-g is not solely responsible for
HSVd-5 / Control Ab d 3/7 66 PFU/ml antagonizing HSV-1 replication in the eye since treatmentHSVd-5 / anti-IFN-a/b Ab e 6/6 1922 PFU/ml
of immunized mice with anti-IFN-g Ab had no effect onHSVd-5 / anti-IFN-a Ab f 2/7 1200 PFU/ml
the survival of the mice even though it significantly re-
a Mice (n  6–7/group) were immunized with heat-inactivated virus duced serum levels of IFN-g. Although unproven, it is
5 days prior to ocular inoculation with HSV-1. Mice were subsequently tempting to speculate that the increase in cytokine gene
sacrificed on day 7 p.i. and the TG were homogenized in HBSS and
expression in the TG is an adaptive response directedthe supernatant was placed in culture with CV-1 indicator cells in
toward controlling viral replication in the TG early in thefivefold dilutions. Cultures of CV-1 were enumerated for plaques 48 hr
following the addition of TG homogenized samples. infection due to the reduction of type 1 IFNs. Collectively,
b Reported as fraction of mice TG that had detectable HSV-1. the findings would suggest that immune events (primarily
c Numbers are the mean PFU/ml of HSV-1 in samples positive for innate and cellular) within the local microenvironment of
HSV-1.
the TG play a major role in determining the outcome ofd Heat-inactivated HSV-1 given 5 days prior to infection. Normal rab-
HSV-1 replication and the establishment of latency follow-bit serum administered 5 and 2 days prior to infection.
e Heat-inactivated HSV-1 given 5 days prior to infection. Anti-IFN-a/ ing ocular infection as indicated by the changes in the
b Ab (neutralization capacity  500 units/injection) given 5 and 2 days cytokine and immune effector cell (CD8/) expression be-
prior to infection. tween uninfected and latently infected mice treated withf Heat-inactivated HSV-1 given 5 days prior to infection. Anti-IFN–
or without anti-IFN-a/b antibody.aAb (neutralization capacity  500 units/injection) given 5 and 2 days
prior to infection.
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